2025 Q4 -tulosraportti
12 päivää sitten
‧1 t 1 min
7,95 DKK/osake
Irtoamispäivä 27.3.
3,79%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
714
Myynti
Määrä
1 188
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 72 | - | - | ||
| 4 | - | - | ||
| 19 | - | - | ||
| 66 | - | - | ||
| 148 | - | - |
Ylin
311,55VWAP
Alin
307,6VaihtoMäärä
395 1 275 073
VWAP
Ylin
311,55Alin
307,6VaihtoMäärä
395 1 275 073
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 12 000 | 12 000 | 0 | 12 000 |
| Anonyymi | 1 320 478 | 1 320 478 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 12 000 | 12 000 | 0 | 12 000 |
| Anonyymi | 1 320 478 | 1 320 478 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 5.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
Alle minuutti sittenAlle minuutti sittenNN aktien har de seneste 10 år (med dagens kurs) præsteret godt 6 procent om året ex. udbytte. Er det hvad man kan forvente af en aktie med den succes NN trods alt har - eller er den i virkeligheden udsat for kurstæsk på kurstæsk. Den forretning vi så for 10 år siden var jo en bolsjebutik i forhold til det NN er i dag, er bekymringen virkelig at vi skal tilbage dertil?
·2 t sittenhttps://e24.no/boers-og-finans/i/vr5d24/loaded-up-for-billion-after-novo-nordisk-hit
·3 t sittenWhen everyone slaughters Novo – is that when it turns around? I have noticed one thing over the years: When the mood is at its darkest, the comment sections are boiling, and Finansavisen really brings out the slaughter knife – that's often when a turning point is approaching. Some time ago, Karl Johan Moldnes strongly criticized Novo on Børsmorgen. The message was clear: price pressure in the USA, increasing competition, patent expiry, margin pressure, uncertainty around volume growth. The narrative was practically that the party is over. And yes – there are real challenges. It's not that. But the interesting thing is the timing. The last time Moldnes was truly merciless towards a company I followed closely, it was Wilh. Wilhelmsen Holding. The mood was heavy, many had given up, and most things were interpreted negatively. Afterwards, the share has risen nearly 100 %. The same pattern has repeated itself in several companies in recent years: strong negative media coverage near the bottom – before the repricing comes when the market realizes that it perhaps got a bit too dark. Is it a coincidence? Maybe. But the market tends to overreact – especially when the narrative becomes one-sided. Looking at Novo now: • Prices in the USA are coming down – but volumes can increase sharply. • Medicare expansion can open up for millions of new patients. • The Wegovy pill represents a new and broader market. • Catalent capacity provides better supply control from 2026. • The total market for obesity treatment is still growing explosively. When everyone talks about the risk, it's often because much is already discounted in the price. I'm not saying this is the bottom – nobody knows that. But history shows that when the consensus is that “now everything is destroyed”, that's rarely the start of the worst downturn. Perhaps we are closer to capitulation than collapse. What do you think – is this a classic overreaction, or has the case structurally weakened?
·32 min sittenIf this is the bottom, we will only know in quite some time. Right now, a Bear flag is playing out, which has not yet decided. If that scenario is to play out, the potential lies towards the lower 200 Kr. - everything is cancelled upon a break with good volume above 350 kr. - shorts come into play around 222 - 230 kr. - we have a gap at 295,- and it must not close below 295 kr. :-) Is Novo undervalued - I believe it is. It can therefore well fall to 200 - 225 Kr. - it certainly can, no problem with that.
·3 t sitten · MuokattuOne can feel the FOMO in the stomach :D.. I have it, but will stay out a bit longer. Now that all analysts agree that Novo must not make any missteps during 2026 (not even a fine-tuning in the lower negative forecasting will be acceptable), I read that as Novo being fully aware of it. I wonder if they have played it safe when they made the forecasting.. And I wonder if Mike is the right man to scale up marketing and sales of weight-loss medication as consumer products, instead of patient care.
·4 t sittenReady for today's Sivert?
·1 t sittenYou are at least leaking out of my comment section, unnecessary noise that deserves to be Muted 🤷♂️
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
12 päivää sitten
‧1 t 1 min
7,95 DKK/osake
Irtoamispäivä 27.3.
3,79%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- Alle minuutti sittenAlle minuutti sittenNN aktien har de seneste 10 år (med dagens kurs) præsteret godt 6 procent om året ex. udbytte. Er det hvad man kan forvente af en aktie med den succes NN trods alt har - eller er den i virkeligheden udsat for kurstæsk på kurstæsk. Den forretning vi så for 10 år siden var jo en bolsjebutik i forhold til det NN er i dag, er bekymringen virkelig at vi skal tilbage dertil?
- ·2 t sittenhttps://e24.no/boers-og-finans/i/vr5d24/loaded-up-for-billion-after-novo-nordisk-hit
- ·3 t sittenWhen everyone slaughters Novo – is that when it turns around? I have noticed one thing over the years: When the mood is at its darkest, the comment sections are boiling, and Finansavisen really brings out the slaughter knife – that's often when a turning point is approaching. Some time ago, Karl Johan Moldnes strongly criticized Novo on Børsmorgen. The message was clear: price pressure in the USA, increasing competition, patent expiry, margin pressure, uncertainty around volume growth. The narrative was practically that the party is over. And yes – there are real challenges. It's not that. But the interesting thing is the timing. The last time Moldnes was truly merciless towards a company I followed closely, it was Wilh. Wilhelmsen Holding. The mood was heavy, many had given up, and most things were interpreted negatively. Afterwards, the share has risen nearly 100 %. The same pattern has repeated itself in several companies in recent years: strong negative media coverage near the bottom – before the repricing comes when the market realizes that it perhaps got a bit too dark. Is it a coincidence? Maybe. But the market tends to overreact – especially when the narrative becomes one-sided. Looking at Novo now: • Prices in the USA are coming down – but volumes can increase sharply. • Medicare expansion can open up for millions of new patients. • The Wegovy pill represents a new and broader market. • Catalent capacity provides better supply control from 2026. • The total market for obesity treatment is still growing explosively. When everyone talks about the risk, it's often because much is already discounted in the price. I'm not saying this is the bottom – nobody knows that. But history shows that when the consensus is that “now everything is destroyed”, that's rarely the start of the worst downturn. Perhaps we are closer to capitulation than collapse. What do you think – is this a classic overreaction, or has the case structurally weakened?·32 min sittenIf this is the bottom, we will only know in quite some time. Right now, a Bear flag is playing out, which has not yet decided. If that scenario is to play out, the potential lies towards the lower 200 Kr. - everything is cancelled upon a break with good volume above 350 kr. - shorts come into play around 222 - 230 kr. - we have a gap at 295,- and it must not close below 295 kr. :-) Is Novo undervalued - I believe it is. It can therefore well fall to 200 - 225 Kr. - it certainly can, no problem with that.
- ·3 t sitten · MuokattuOne can feel the FOMO in the stomach :D.. I have it, but will stay out a bit longer. Now that all analysts agree that Novo must not make any missteps during 2026 (not even a fine-tuning in the lower negative forecasting will be acceptable), I read that as Novo being fully aware of it. I wonder if they have played it safe when they made the forecasting.. And I wonder if Mike is the right man to scale up marketing and sales of weight-loss medication as consumer products, instead of patient care.
- ·4 t sittenReady for today's Sivert?·1 t sittenYou are at least leaking out of my comment section, unnecessary noise that deserves to be Muted 🤷♂️
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
714
Myynti
Määrä
1 188
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 72 | - | - | ||
| 4 | - | - | ||
| 19 | - | - | ||
| 66 | - | - | ||
| 148 | - | - |
Ylin
311,55VWAP
Alin
307,6VaihtoMäärä
395 1 275 073
VWAP
Ylin
311,55Alin
307,6VaihtoMäärä
395 1 275 073
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 12 000 | 12 000 | 0 | 12 000 |
| Anonyymi | 1 320 478 | 1 320 478 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 12 000 | 12 000 | 0 | 12 000 |
| Anonyymi | 1 320 478 | 1 320 478 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 5.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2025 Q4 -tulosraportti
12 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 5.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
7,95 DKK/osake
Irtoamispäivä 27.3.
3,79%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- Alle minuutti sittenAlle minuutti sittenNN aktien har de seneste 10 år (med dagens kurs) præsteret godt 6 procent om året ex. udbytte. Er det hvad man kan forvente af en aktie med den succes NN trods alt har - eller er den i virkeligheden udsat for kurstæsk på kurstæsk. Den forretning vi så for 10 år siden var jo en bolsjebutik i forhold til det NN er i dag, er bekymringen virkelig at vi skal tilbage dertil?
- ·2 t sittenhttps://e24.no/boers-og-finans/i/vr5d24/loaded-up-for-billion-after-novo-nordisk-hit
- ·3 t sittenWhen everyone slaughters Novo – is that when it turns around? I have noticed one thing over the years: When the mood is at its darkest, the comment sections are boiling, and Finansavisen really brings out the slaughter knife – that's often when a turning point is approaching. Some time ago, Karl Johan Moldnes strongly criticized Novo on Børsmorgen. The message was clear: price pressure in the USA, increasing competition, patent expiry, margin pressure, uncertainty around volume growth. The narrative was practically that the party is over. And yes – there are real challenges. It's not that. But the interesting thing is the timing. The last time Moldnes was truly merciless towards a company I followed closely, it was Wilh. Wilhelmsen Holding. The mood was heavy, many had given up, and most things were interpreted negatively. Afterwards, the share has risen nearly 100 %. The same pattern has repeated itself in several companies in recent years: strong negative media coverage near the bottom – before the repricing comes when the market realizes that it perhaps got a bit too dark. Is it a coincidence? Maybe. But the market tends to overreact – especially when the narrative becomes one-sided. Looking at Novo now: • Prices in the USA are coming down – but volumes can increase sharply. • Medicare expansion can open up for millions of new patients. • The Wegovy pill represents a new and broader market. • Catalent capacity provides better supply control from 2026. • The total market for obesity treatment is still growing explosively. When everyone talks about the risk, it's often because much is already discounted in the price. I'm not saying this is the bottom – nobody knows that. But history shows that when the consensus is that “now everything is destroyed”, that's rarely the start of the worst downturn. Perhaps we are closer to capitulation than collapse. What do you think – is this a classic overreaction, or has the case structurally weakened?·32 min sittenIf this is the bottom, we will only know in quite some time. Right now, a Bear flag is playing out, which has not yet decided. If that scenario is to play out, the potential lies towards the lower 200 Kr. - everything is cancelled upon a break with good volume above 350 kr. - shorts come into play around 222 - 230 kr. - we have a gap at 295,- and it must not close below 295 kr. :-) Is Novo undervalued - I believe it is. It can therefore well fall to 200 - 225 Kr. - it certainly can, no problem with that.
- ·3 t sitten · MuokattuOne can feel the FOMO in the stomach :D.. I have it, but will stay out a bit longer. Now that all analysts agree that Novo must not make any missteps during 2026 (not even a fine-tuning in the lower negative forecasting will be acceptable), I read that as Novo being fully aware of it. I wonder if they have played it safe when they made the forecasting.. And I wonder if Mike is the right man to scale up marketing and sales of weight-loss medication as consumer products, instead of patient care.
- ·4 t sittenReady for today's Sivert?·1 t sittenYou are at least leaking out of my comment section, unnecessary noise that deserves to be Muted 🤷♂️
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
714
Myynti
Määrä
1 188
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 72 | - | - | ||
| 4 | - | - | ||
| 19 | - | - | ||
| 66 | - | - | ||
| 148 | - | - |
Ylin
311,55VWAP
Alin
307,6VaihtoMäärä
395 1 275 073
VWAP
Ylin
311,55Alin
307,6VaihtoMäärä
395 1 275 073
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 12 000 | 12 000 | 0 | 12 000 |
| Anonyymi | 1 320 478 | 1 320 478 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 12 000 | 12 000 | 0 | 12 000 |
| Anonyymi | 1 320 478 | 1 320 478 | 0 | 0 |